-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Dolphin Congratulates Shore Fire Media and Its Clients on 20 GRAMMY(R) Nominations, Including 10 Best Album Nods Across Diverse Genres
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
5E Advanced Materials Highlights Commercial Momentum in First Month as an Operating Borates Producer
-
Trout CPA Expands Partner Leadership with Michael Carr and Dan Lerew
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Jumia Reports Third Quarter 2026 Results
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
What to Do When Two Households Become One
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago
SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the company's ongoing clinical development program for crofelemerfor the treatment of microvillus inclusion disease (MVID), an ultrarare pediatric disorder. Members of Napo's Scientific Advisory Board will join Napo and Jaguar representatives at the meeting.
"We're very pleased that Napo has been granted a meeting with the FDA to discuss Napo's development plans for crofelemer for MVID - a devastating pediatric disease characterized by severe malabsorption that requires life-sustaining parenteral support to meet the nutritional, fluid and electrolyte requirements of the child, and for which there no approved drug treatments," said Pravin Chaturvedi, PhD, Napo's and Jaguar's Chief Scientific Officer and Chair of the Scientific Advisory Board. "A core Napo goal for this meeting is to obtain input from the FDA on the clinical program and potential expedited regulatory pathways for this rare orphan indication."
As announced, and as presented April 26, 2025 at the Annual ELITE PED-GI Congress, the initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) of a novel crofelemer powder formulation for oral solution in Abu Dhabi in the United Arab Emirates show that crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in the first participating MVID patient by up to 27%. An abstract describing the initial results of this trial has been accepted for presentation at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place November 5-8, 2025 in Chicago.
Jaguar, through Napo, is supporting the independent proof-of-concept IIT in pediatric intestinal failure (IF) patients at Sheikh Khalifa Medical City in Abu Dhabi, and is conducting the placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients with IF at sites in the U.S., European Union, and Middle East/North Africa regions under appropriate regulatory approvals in each of these geographies.
"Given the ultrarare nature of MVID, and the groundbreaking initial proof-of-concept results from the IIT in Abu Dhabi, even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval," said Lisa Conte, Jaguar's Founder and CEO.
Based on the initial findings from the IIT in Abu Dhabi, crofelemer's paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Napo personnel will meet with the FDA to discuss Napo's development plans for crofelemer for MVID, statements regarding Jaguar's expectation that an abstract describing the results of the investigator-initiated trial in Abu Dhabi will be presented at NASPGHAN 2025, Jaguar's expectation that even a small number of MVID patients showing benefit with crofelemer may allow Napo to explore pathways for expedited regulatory approval, and Jaguar's expectation that crofelemer's paradigm-shifting mechanism of action has the potential to provide a novel therapeutic option to reduce parenteral support and associated complications in MVID patients. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
[email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
D.Johnson--AT